Significance of the Differential Peptidome in Multidrug-Resistant Tuberculosis

被引:7
|
作者
Yang, Yan [1 ,2 ]
Wu, Jianqing [1 ]
机构
[1] Nanjing Med Univ, Dept Geriatr, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China
[2] Second Hosp Nanjing, Dept TB, Nanjing 210003, Jiangsu, Peoples R China
基金
对外科技合作项目(国际科技项目); 中国国家自然科学基金;
关键词
MYCOBACTERIUM-TUBERCULOSIS; DEVELOPING-COUNTRIES; PROTEOMIC ANALYSIS; IDENTIFICATION; SYSTEMS; IL-6; PCR;
D O I
10.1155/2019/5653424
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Most multidrug-resistant tuberculosis (MDR-TB) patients fail to receive a timely diagnosis and treatment. Therefore, we explored the differentially expressed peptides in MDR-TB compared with drug-susceptible tuberculosis (DS-TB) patients using LC-MS/MS and Ingenuity Pathway Analysis (IPA) to analyse the potential significance of these differentially expressed peptides. A total of 301 peptides were differentially expressed between MDR-TB and DS-TB groups. Of these, 24 and 16 peptides exhibited presented high (fold change 2.0, P < 0.05) and low (fold change -2.0, P < 0.05) levels in MDR-TB. Significant canonical pathways included the prothrombin activation system, coagulation system, and complement system. In the network of differentially expressed precursor proteins, lipopolysaccharide (LPS) regulates many precursor proteins, including four proteins correlated with organism survival. These four important differentially expressed proteins are prothrombin (F2), complement receptor type 2 (CR2), collagen alpha-2(V) chain (COL5A2), and inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4). After addition of CR2 peptide, IL-6 mRNA expression in THP-1 cells decreased significantly in dose- and time-dependent manners. Cumulatively, our study proposes potential biomarkers for MDR-TB diagnosis and enables a better understanding of the pathogenesis of MDR-TB. The functions of differentially expressed peptides, especially CR2, in MDR-TB require further investigation.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Multidrug-resistant tuberculosis
    Moreira Lemos, Antonio Carlos
    Matos, Eliana Dias
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2013, 17 (02) : 239 - 246
  • [2] Multidrug-resistant tuberculosis
    Dheda, Keertan
    Mirzayev, Fuad
    Cirillo, Daniela Maria
    Udwadia, Zarir
    Dooley, Kelly E.
    Chang, Kwok-Chiu
    Omar, Shaheed Vally
    Reuter, Anja
    Perumal, Tahlia
    Horsburgh, C. Robert
    Murray, Megan
    Lange, Christoph
    NATURE REVIEWS DISEASE PRIMERS, 2024, 10 (01)
  • [3] Multidrug-resistant Tuberculosis
    Lynch, John B.
    MEDICAL CLINICS OF NORTH AMERICA, 2013, 97 (04) : 553 - +
  • [4] Multidrug-resistant tuberculosis
    Wulandari, Dika Apriliana
    Hartati, Yeni Wahyuni
    Ibrahim, Abdullahi Umar
    Pitaloka, Dian Ayu Eka
    Irkham
    CLINICA CHIMICA ACTA, 2024, 559
  • [5] An update on multidrug-resistant tuberculosis
    Park, Mirae
    Satta, Giovanni
    Kon, Onn Min
    CLINICAL MEDICINE, 2019, 19 (02) : 135 - 139
  • [6] Linezolid for multidrug-resistant tuberculosis
    Chang, Kwok-Chiu
    Leung, Chi-Chiu
    Daley, Charles L.
    LANCET INFECTIOUS DISEASES, 2012, 12 (07) : 502 - 503
  • [7] Management of Multidrug-Resistant Tuberculosis
    Daley, Charles L.
    Caminero, Jose A.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 39 (03) : 310 - 324
  • [8] Delamanid in the treatment of multidrug-resistant tuberculosis
    Gupta, R.
    Wells, C. D.
    Hittel, N.
    Hafkin, J.
    Geiter, L. J.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2016, 20 (12) : S33 - S37
  • [9] Novel treatments in multidrug-resistant tuberculosis
    Mondoni, Michele
    Saderi, Laura
    Sotgiu, Giovanni
    CURRENT OPINION IN PHARMACOLOGY, 2021, 59 : 103 - 115
  • [10] Linezolid in the Treatment of Multidrug-Resistant Tuberculosis
    Schecter, G. F.
    Scott, C.
    True, L.
    Raftery, A.
    Flood, J.
    Mase, S.
    CLINICAL INFECTIOUS DISEASES, 2010, 50 (01) : 49 - 55